Mission Statement

Bioxytran is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design.
Sign up for bioxytran updates

Glycovirology

Glycovirology is a novel glycan-based platform technology.
Learn More

Degenerative Diseases

Bioxytran is developing an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention.
Learn More

Glycovirology

Glycovirology is a novel glycan-based platform technology. The concept behind it is that carbohydrate drugs can be used as entry inhibitors that attach directly to the binding domain of different viruses.  Our main drug candidate is designed to target the virus instead of the cell like most of the other compounds in development.  There is also evidence that carbohydrate drugs are capable of modulating the immune system.

Learn More

Hypoxia and Degenerative Diseases

Bioxytran is developing an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Our initial targeted medical conditions are brain stroke, wound healing, and trauma. Most of these disease indications can use hyperbaric treatment, but it is costly and limited.  In these indications hyperbaric treatment shows promise, but the duration of treatment is limited due to oxygen toxicity our oxygen transport molecule has the ability to impact the duration of treatment due to its drug design.

Learn More

Pipeline

Bioxytran is developing two platform technologies in the fields of Glycovirology and Hypoxia and Degenerative Diseases. Learn more about our ProLectin & BXT pipelines here.

Learn More
news

Latest articles

Bioxtyran (OTCMKTS: BIXT) Licenses Phase 2 Asset for COVID-19 Patients After Finding Smoking Gun Journal Article
Mar 25, 2020

Bioxytran Inc. (OTCMKTS: BIXT) has a development stage hypoxia drug that that was initially targeting Acute Respiratory Distress Syndrome (ARDS) and stroke. Today they announced the licensing of a potentially phase 2 ready viral inhibitor which is designed to bind to a receptor on the protein spike of the virus.

BXT-25: A New Solution for Late Stage Treatment of Wuhan Coronavirus
Feb 13, 2020

Bioxytran Inc., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the lungs, brain, heart, and other vital organs offers a new and possibly life-saving treatment option for late-stage 2019-nCoV.

Scientific Background How cells sense and adapt to oxygen availability
Nov 8, 2019

The Nobel Prize in Physiology or Medicine for 2019 is awarded to William Kaelin, Jr., Sir Peter Ratcliffe, and Gregg Semenza. The need for oxygen to sustain life has been understood since the onset of modern biology; but the molecular mechanisms underlying how cells adapt to variations in oxygen supply were unknown until the prize-winning work described here. Animal cells undergo fundamental shifts in gene expression when there are changes in the oxygen levels around them. 

see all
team

Lorem Ipsum

Mike Sheikh
EVP Business Development
BS
Ola Soderquist
CFO
CPA, CMA, CM&AA
Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC).
David Platt
CEO & Chairman
PhD
Dr. Platt is a world-renowned expert in carbohydrate chemistry who has founded three publicly traded companies, creating nearly $1B for investors. He has raised $150M directly in public markets in the U.S., and has led development of two drug candidates from concept through phase II clinical trials.

Team

Learn more about the team from BioxyTran

Investors

Learn more about BioxyTran investors and S1 Stocks

News

Join the conversation as we discuss Bioxytran's use-cases, development progress, and more.